Clinical Trials

NCT Number: NCT04857502 Phase: Early Phase 1 Trial Summary: This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I&S in patients with prostate cancer who undergo pelvic lymph node dissection. Pr – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jonsson Comprehensive Cancer Center Acronym:

NCT Number: NCT04879940 Phase: PHASE2 Trial Summary: This is a Phase II prospective clinical trial in which patients with prostate carcinoma and obstructive lower urinary tract symptoms electing for radiation therapy will undergo Pro – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): H. Lee Moffitt Cancer Center and Research Institute Acronym:

NCT Number: NCT04763915 Phase: NA Trial Summary: The IMPACT Study seeks to refine and evaluate the effectiveness of interventions on improving guideline-adherent cancer risk management (CRM) and family communication (FC) of genet – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Vanderbilt-Ingram Cancer Center Acronym: IMPACT

NCT Number: NCT04725903 Phase: Not Applicable Trial Summary: This phase II trial investigates whether proton radiation therapy directed to the prostate tumor, pelvic, and para-aortic lymph nodes, is an effective way to treat patients with hi – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Emory University|National Cancer Institute (NCI) Acronym:

NCT Number: NCT04734730 Phase: Phase 2 Trial Summary: This phase II trial studies the effect of talazoparib with androgen deprivation therapy and abiraterone in treating castration sensitive prostate cancer patients. Talazoparib is an – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): City of Hope Medical Center|National Cancer Institute (NCI) Acronym:

NCT Number: NCT04748042 Phase: Phase 2 Trial Summary: The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prost – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym:

NCT Number: NCT04731844 Phase: Phase 2 Trial Summary: To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Rochester Acronym:

NCT Number: NCT04700332 Phase: Phase 2 Trial Summary: The standard of care imaging of prostate cancer metastases recommended by the National Comprehensive Cancer Network (NCCN), CT of the chest/abdomen/pelvis and bone scan, may be sub – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Hoag Memorial Hospital Presbyterian Acronym:

NCT Number: NCT04691804 Phase: Phase 3 Trial Summary: To evaluate whether Fuzuloparib plus AA-P is superior to placebo plus AA-P as first-line treatment by assessment of radiographic progression-free survival (rPFS) in mCRPC subjects – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Jiangsu HengRui Medicine Co., Ltd. Acronym:

NCT Number: NCT04693377 Phase: Not Applicable Trial Summary: This trial compares cryoablation combined with stereotactic body radiation therapy to stereotactic body radiation therapy alone to see how well they work in treating patients with – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym: